Current understanding of human megakaryocytic-erythroid progenitors and their fate determinants

Purpose of review This review focuses on our current understanding of fate decisions in bipotent megakaryocyte-erythroid progenitors (MEPs). Although extensive research has been carried out over decades, our understanding of how MEP commit to the erythroid versus megakaryocyte fate remains unclear. Recent findings We discuss the isolation of primary human MEP, and focus on gene expression patterns, epigenetics, transcription factors and extrinsic factors that have been implicated in MEP fate determination. We conclude with an overview of the open debates in the field of MEP biology. Summary Understanding MEP fate is important because defects in megakaryocyte and erythrocyte development lead to disease states such as anaemia, thrombocytopenia and leukaemia. MEP also represent a model system for studying fundamental principles underlying cell fate decisions of bipotent and pluripotent progenitors, such that discoveries in MEP are broadly applicable to stem/progenitor cell biology.
Source: Current Opinion in Hematology - Category: Hematology Tags: MYELOID BIOLOGY: Edited by H. Leighton Grimes Source Type: research

Related Links:

AbstractGilteritinib (Xospata®), a next-generation tyrosine kinase inhibitor (TKI), is approved in several countries/regions worldwide for the treatment of relapsed or refractory acute myeloid leukaemia (AML) in adults with FMS-like tyrosine kinase 3 (FLT3) mutations. In this patient population, oral gilteritinib significantly improved overall survival (OS) and the response rate for complete remission with full or partial haematological recovery compared with salvage chemotherapy in the phase III ADMIRAL trial. In an integrated safety analysis of patients with relapsed or refractory AML, the most commonly reported grad...
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
Abstract Aging is associated with a higher risk of developing malignant diseases, including myelodysplastic syndromes, clonal disorders characterised by chronic cytopenias (anaemia, neutropenia and thrombocytopenia) and abnormal cellular maturation. Myelodysplastic syndromes arising in older subjects are influenced by combinations of acquired somatic genetic lesions driving evolution from clonal haematopoiesis to myelodysplastic syndromes and from myelodysplastic syndromes to acute leukaemia. A different pattern of mutations has been identified in a small subset of myelodysplastic syndromes arising in young patien...
Source: Aging Clinical and Experimental Research - Category: Geriatrics Authors: Tags: Aging Clin Exp Res Source Type: research
AbstractT-lymphoblastic leukemia/lymphoma (T-ALL/LBL) with anyJAK2 gene fusion is rarely reported. Here, we report a case of T-ALL with a novelTBL1XR1-JAK2 gene fusion in a 5-year-old boy. His lab showed a high white blood cell count, mild anemia, moderate thrombocytopenia, and concurrently increased eosinophils (absolute eosinophil count: 4  × 10^9/L). Peripheral blood and bone marrow aspirate smears showed>  90% mononucleated blasts. Flow cytometry on peripheral blood revealed a large blast population positive for CD2, surface CD3 (
Source: Journal of Hematopathology - Category: Pathology Source Type: research
The oral repercussions of patients with leukemia include the reduction of the production of blood cells that can lead to anemia, neutropenia, and thrombocytopenia. This work aims to report on the oral repercussions and dental management of patients with leukemia. A 42-year-old woman with a recent diagnosis of acute myeloid leukemia during the chemotherapy underwent oral opening limitation, with a complaint of odynophagia and low dietary intake, consuming only liquid consistency food. Lip dryness with erosive areas, an increase of volume in the upper lip, and presence of hyperplasia and ecchymoses in the gingival margin and...
Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics - Category: ENT & OMF Authors: Tags: 20190195 Source Type: research
In this study, we present a case of ALL who was diagnosed with CCHF simultaneously. A 43-year old female patient who works in the library and does not have a chronic disease other than asthma and thyroid disorder, has admitted to our hospital with the complaints of intermittent fever, weakness, generalized joint and body pain for about 3 weeks. She had fever and the physical examination revealed bilateral cervical and right postauricular lymphadenopathies. Her aspartate aminotransferase: 77 U/L, alanine aminotransferase: 117 U/L, lactate dehydrogenase: 616 U/L, hemoglobin: 8.27 g/dl, leukocyte count: 15.690/mm3 , neutrophi...
Source: Mikrobiyoloji Bulteni - Category: Microbiology Tags: Mikrobiyol Bul Source Type: research
Patients with MDS are clinically subdivided into lower-risk (very low/low/intermediate risk) and higher-risk (high/very high risk) disease according to the revised International Prognostic Scoring System (IPSS-R) risk score [1,2]. Patients with lower-risk MDS are affected primarily by symptoms of chronic anemia and fatigue [3]. Patients with neutropenia and thrombocytopenia are at increased risk for infection, bleeding, and also progression to acute myelogenous leukemia [2]. In a study of patients with lower-risk MDS, hemoglobin level was the most important independent predictor of health-related quality of life [4].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Discussion Pediatric cancers in the US number about 12,000 per year. After injury, it is the second leading cause of death in children and adolescents. Cancer presentations vary widely, but often begin with non-specific symptoms that continue or progress depending on the location and tumor type. Patients can present with oncological emergencies especially if there are mechanical obstruction such as superior vena cava syndrome or cerebral herniation. More commonly are infections due to immunosuppression. Cancer treatment also causes its own myriad of problems that clinicians need to be aware of to diagnosis and treat, but a...
Source: PediatricEducation.org - Category: Pediatrics Authors: Tags: Uncategorized Source Type: news
Basel, 13 June 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive results from the phase III VIALE-A study, evaluating Venclexta ®/Venclyxto® (venetoclax) in combination with azacitidine in people with previously untreated acute myeloid leukaemia (AML) who were ineligible for intensive induction chemotherapy. VIALE-A results were featured in the 25th European Hematology Association Virtual Congress Press Briefing on Saturda y 13 June 2020 at 08:30 CEST and will be presented at the congress during the Late-breaking Oral Session (abstract #LB2601) on Sunday 14 June 2020.“We are very pleased to p...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
Conclusion: Monocytopenia, especially anemia, was the most common type of cytopenia. The cytopenia was predominantly grade 2, developed in majority of the patients within 6 months after imatinib initiation, and had resolved by 24-36 months after imatinib initiation. PMID: 32454829 [PubMed]
Source: Advances in Hematology - Category: Hematology Tags: Adv Hematol Source Type: research
In conclusion, EPAG was well-tolerated and effective in restoring hematopoiesis in patients with low to intermediate-1 risk MDS. This study was registered at clinicaltrials.gov as #NCT00932156. PMID: 32439728 [PubMed - as supplied by publisher]
Source: Haematologica - Category: Hematology Authors: Tags: Haematologica Source Type: research
More News: Anemia | Biology | Cytology | Genetics | Hematology | Leukemia | Nicotine | Thrombocytopenia